LeMaitre Vascular (NASDAQ:LMAT) Receives “Outperform” Rating from Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note released on Friday morning, Benzinga reports. Oppenheimer currently has a $93.00 price target on the medical instruments supplier’s stock, up from their prior price target of $90.00.

LMAT has been the topic of several other reports. JMP Securities lifted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Barrington Research boosted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded up $6.49 during trading on Friday, hitting $94.88. 343,645 shares of the company’s stock traded hands, compared to its average volume of 123,348. The firm’s fifty day moving average price is $89.59 and its 200 day moving average price is $82.98. LeMaitre Vascular has a twelve month low of $45.96 and a twelve month high of $101.67. The company has a market cap of $2.13 billion, a PE ratio of 56.81, a PEG ratio of 2.33 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period in the previous year, the business earned $0.33 EPS. The firm’s revenue was up 15.6% on a year-over-year basis. As a group, equities research analysts anticipate that LeMaitre Vascular will post 1.86 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is presently 38.32%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the business. CANADA LIFE ASSURANCE Co raised its stake in shares of LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after buying an additional 6,875 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of LeMaitre Vascular by 1,001.4% during the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after buying an additional 6,669 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares during the last quarter. Quadrature Capital Ltd raised its stake in shares of LeMaitre Vascular by 129.4% during the first quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after buying an additional 12,654 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of LeMaitre Vascular by 554.7% during the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after buying an additional 47,218 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.